New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc.

PASG

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

3.92 0.31 +8.59%
Market cap
$11.6M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.0×
Payout ratio
—

Capital & Financial Ratios $m

Size
Market Cap 12
Revenue ttm —
Net income ttm (33)
Free cash flow ttm (33)
Net debt Q (20)
Valuation
P/E n/m
Forward P/E e —
Price / sales —
Forward P/S e Powerpack
Price / FCF n/m
Price / book 253.6 (above 6: high)
Financial health
Current ratio Q 1.0
Debt / equity Q n/m
Interest coverage Q (24.1)
Growth
Revenue growth e —
EPS growth e +46.0% (at or above 15%: strong)
EPS growth e +49.6% (at or above 15%: strong)
EPS growth, 5 yrs e +14.8%
Insiders
Net bought 12m 0
Sells 12m 2
Buys 12m 1
Owned by insiders 7.7%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales — — —
Cash Flow — — 0.00%
Earnings — — 0.00%
Book Value — (42.74%) (54.67%)

Valuation

P/B against its own 10 years 99.22%
10-year low 10-year high
EV/FCF against its own 10 years 3.55%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — — — — — — — — — — — — — —
Gross margin, % — — — 0.00 0.00 0.00 0.00 — — — — 0.0 pt
EBT — — (13) (46) (112) (185) (136) (102) (65) (46) (33) n/m
EBT margin, % — — — — — — — — — — — —
Net income — 0 (13) (46) (112) (185) (136) (102) (65) (46) (33) n/m
Per share, $
Per share, $ Revenue — — — — — — — — — — — —
Earnings — — (0.28) (215.46) (58.20) (69.60) (50.00) (37.20) (21.40) (14.35) (10.35) n/m
Cash flow — — (0.41) (188.37) (41.70) (47.57) (43.44) (28.59) (15.58) (9.93) (10.14) n/m
Capex — — 0.00 (7.99) (0.85) (9.61) (1.94) (0.05) (0.01) 0.37 0.01 n/m
Free cash flow — — (0.41) (196.36) (42.56) (57.18) (45.37) (28.65) (15.59) (9.56) (10.14) n/m
Book value — — (0.27) (265.59) 157.82 119.47 73.99 40.66 19.90 5.91 0.02 n/m
Shares, m — — 46 0 2 3 3 3 3 3 3 (31.7%)
Valuation, ×
Valuation, × P/E — — — — — — — — — — n/m —
P/S — — — — — — — — — — — —
P/B — — — — — — — — — — 0 —
EV/Sales — — — — — — — — — — — —
EV/FCF — — — — — — — — — — 0 —
Cash, $m
Cash, $m Operating cash flow — — (19) (40) (81) (127) (118) (78) (48) (32) (33) n/m
Capex — — (3) (2) (2) (26) (5) 0 0 1 0 n/m
Free cash flow — — (19) (42) (82) (153) (123) (78) (48) (30) (33) n/m
Balance, $m
Balance, $m Working capital — — 33 162 296 296 179 102 59 25 0 (4.1%)
Net debt — — (25) (159) (305) (316) (190) (114) (77) (46) (20) n/m
Shareholders’ equity — — (12) (56) 305 319 201 111 61 19 0 n/m
Returns, %
Returns, % ROA — — (76.33) (43.04) (44.31) (54.28) (45.48) (51.80) (51.21) (55.28) (69.68) +21.1 pt
ROIC — — — 0.00 0.00 (4,024.99) (735.76) 0.00 0.00 0.00 0.00 0.0 pt
ROE — — 37.32 133.38 (90.34) (59.48) (52.35) (65.29) (75.07) (113.78) (212.27) (151.1) pt
People
People Employees — — — 20 74 133 85 58 60 24 — +3.1%
Revenue/emp, $m — — — — — — — — — — — —
Negative figures in brackets.
estimates

All 10 years →

Fundamentals updated Nov 12, 2026

Passage Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
QNTM Quantum Biopharma Ltd. $12.6M — (loss-making) — (loss-making) — n/m −197.94% (below 0%: shrinking) 0.00% (79,749.48%) Compare
NEUP Neuphoria Therapeutics Inc. $12.6M — (loss-making) — (loss-making) — n/m +70.26% (above 0%: growing) 100.00% 43,872.18% Compare
DYAI Dyadic International Inc. $12.5M — (loss-making) — (loss-making) −61.44% (below 0%: shrinking) n/m +19.88% (above 0%: growing) 16.48% (403.56%) Compare
CASIF CASI Pharmaceuticals Inc. $12.4M — (loss-making) — (loss-making) −45.93% (below 0%: shrinking) n/m — 51.14% (147.67%) Compare
JSPR Jasper Therapeutics, Inc. $11.9M — (loss-making) — — n/m +67.81% (above 0%: growing) 0.09% (1,802.16%) Compare
BCDA BioCardia, Inc. $11.7M — (loss-making) — (loss-making) −93.02% (below 0%: shrinking) n/m −2.93% (below 0%: shrinking) 100.00% (54,966.67%) Compare
PASG Passage Bio, Inc. $11.6M — (loss-making) — — n/m +17.68% (above 0%: growing) 0.00% —
AEON AEON Biopharma, Inc. $11.2M — (loss-making) — — n/m −120.53% (below 0%: shrinking) — — Compare
PBM Psyence Biomedical Ltd. $10.9M 0.1× — — n/m −1,628.07% (below 0%: shrinking) — — Compare
Median of peers $12.2M — — −61.44% — −2.93% 33.81% (1,102.86%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed Apr 7, 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.49m 1.53m 58.00
2024 1.64m 902.53k 56.00

Ownership

Directors and executive officers, together 4.90%
Lynx1 Capital Management LP 19.40%
Vestal Point Capital, LP 9.50%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Passage Bio, Inc. (PASG) Latest News

20 more headlines
All PASG news, as stories →
stockrow.com/PASG · Data as of Nov 12, 2026 · For information only; not investment advice. · © 2026 stockrow.com